Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European Medicines Agency’s (EMA) CHMP for use in individuals aged six months and older.

The BioNTech SE ADR BNTX shed 0.20% to $112.28 Friday, on what proved to be an all-around mixed trading session for the stock ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

I am deeply troubled by the growing distrust of science in our society, just at the time when its insights are most needed.

The latest, highly contagious subvariants are driving infections, but new vaccines may help stem the tide of another wave — ...

BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

On Thursday, Aug. 22, the United States Food and Drug Administration (FDA) approved and authorized updated versions of mRNA ...

It’s been over four years since the beginning of the COVID-19 pandemic. And since then, the virus has changed substantially.

Each household can receive up to four free tests from the site COVIDtest.gov. Once ordered, the at-home tests are mailed to ...

Two new COVID-19 strains are circulating globally. Here's what we know about them and what experts anticipate.

The BioNTech SE ADR BNTX slipped 7.29% to $115.62 Wednesday, on what proved to be an all-around rough trading session for the ...

Targeting the KP.2 strain is expected to provide better protection against COVID-19 based on current data. The 2024-2025 mRNA COVID-19 vaccines will include a monovalent component that corresponds to ...